FY2025 EPS Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Lowered by Analyst

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Leerink Partnrs decreased their FY2025 EPS estimates for shares of Aldeyra Therapeutics in a report issued on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will earn $0.50 per share for the year, down from their previous forecast of $0.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.23) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

Several other analysts have also commented on ALDX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday, May 6th. Oppenheimer reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, May 6th. Finally, StockNews.com cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $3.86 on Thursday. The firm has a market capitalization of $229.32 million, a P/E ratio of -7.57 and a beta of 1.45. The stock has a 50-day simple moving average of $3.72 and a two-hundred day simple moving average of $3.59. Aldeyra Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $8.38.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Prime Capital Investment Advisors LLC purchased a new position in Aldeyra Therapeutics during the fourth quarter worth approximately $35,000. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $38,000. NorthRock Partners LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter valued at $42,000. Kingswood Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics in the 1st quarter worth $49,000. Finally, Tower Research Capital LLC TRC raised its position in Aldeyra Therapeutics by 1,064.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 22,167 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 20,264 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.